ArticleScientific reports2025
Association of pan-immune inflammation value with mortality in patients with pulmonary embolism: a cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Association of Triglyceride-to-HDL-C Ratio, Triglyceride-Glucose Index, and Inflammatory Biomarkers with Mortality in Intensive Care Unit Patients with Sepsis.Diagnostics (Basel, Switzerland) · 2026Article
- Pan-Immune-Inflammation Value for Mortality Risk Stratification in Critically Ill Patients With Acute Ischemic Stroke: A Cohort Study Based on the MIMIC-IV Database.CNS neuroscience & therapeutics · 2026Article
- Association between pan-immune-inflammation and in-hospital mortality in critically ill patients with acute pancreatitis: a cohort study from the MIMIC-IV database.BMC gastroenterology · 2026Article
- Observational
- The Role of Early Rehabilitation in Treatment of Acute Pulmonary Embolism-A Narrative Review.Journal of clinical medicine · 2025Review
- Article
- Construction of a Nomogram Model Based on the Pan-Immune-Inflammation Value for Prediction of Adverse Clinical Outcomes in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pan-immune inflammation value (PIV) is associated with prognosis in immune and inflammatory diseases, and inflammation is a hallmark of pulmonary embolism (PE). Nonetheless, the link between PIV and prognosis in PE remains unclear. However, few studies have specifically focused on critically ill patients with PE in ICUs. This study retrospectively analyzed electronic health data of patients with PE from the Medical Information Mart for Intensive Care (MIMIC-IV) database. The primary outcome was 28-day ACM; secondary outcomes were 90-day, 1-year, ICU, and in-hospital mortality. The study population included 213 patients with PE. Multivariate Cox proportional hazards regression showed that elevated PIV was significantly associated with ACM at 28 days (adjusted hazard ratio [aHR]: 1.93; 95% confidence interval [CI]: 1.02-3.63) and 90 days (aHR: 1.96; 95% CI: 1.10-3.47). Further, multivariate logistic regression analysis showed that PIV was significantly and positively associated with the risk of ACM. Kaplan-Meier survival curves showed that PIV was positively associated with ACM. Subgroup and interaction analyses corroborated this correlation. PIV was significantly correlated with ACM in critically ill ICU patients with PE. This correlation highlights the potential utility of PIV for stratifying patients with PE according to their risk of death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.